aidsmap report from the 6th Joint Conference of the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH)
In February this year, the UK government announced that it was expanding NHS England’s initial rollout of long-acting injectable HIV PrEP to 2000 people rather than the 1000 it initially announced last November.
This number is less than 2% of the roughly 111,000 people who have ever started PrEP in England. Although the actual cost negotiated by the NHS is confidential, and likely to be considerably discounted, the list price for the six two-monthly injections of long-acting cabotegravir (Apretude) is roughly £7000 a year. This compares with less than £350 for generic daily PrEP using tenofovir disoproxil/emtricitabine (TDF/FTC) pills.
Given these supply and cost restrictions, local NHS trusts will have to develop their own access criteria for people in need of injectable PrEP. Two presentations at the 6th Joint BHIVA/BASHH Conference gave details of how this is being achieved.
Read more here.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.